Because these Chicago second-graders are bilingual, they may be better protected later in life against the ravages of dementia.
Credit Tim Boyle / Getty Images
The brains of people who grow up speaking two languages are wired differently, and those differences protect them from dementia as they age.
That's the news from two studies out this month from a scientist in Canada who has spent decades trying to figure out whether being bilingual is bad or good. "I've been doing this for 25 years," Ellen Bialystok, a distinguished research professor of psychology at York University in Toronto, tells Shots. "Suddenly people are interested. I figure it's because everybody's scared about dementia."
The FDA says so far it hasn't gotten any reports of patients receiving the fake Altuzan.
Credit U.S. Food And Drug Administration
Another batch of phony cancer drugs has made its way into the U.S., the Food and Drug Administration says.
U.S.-based medical practices purchased vials of counterfeit medicine labeled as Altuzan from a foreign supplier, FDA spokesperson Shelly Burgess tells Shots. She said the agency doesn't have any reports of patients having received the counterfeit drugs.
Altuzan is the Turkish brand name for Avastin, the FDA-approved blockbuster cancer drug from Swiss drugmaker Roche's Genentech unit. Altuzan is approved for use in Turkey — but not in the U.S.
Nine national medical groups are launching a campaign called Choosing Wisely to get U.S. doctors to back off on 45 diagnostic tests, procedures and treatments that often may do patients no good.
Many involve imaging tests such as CT scans, MRIs and X-rays. Stop doing them, the groups say, for most cases of back pain, or on patients who come into the emergency room with a headache or after a fainting spell, or just because somebody's about to undergo surgery.
A nonprofit foundation set up to support scientific research of interest to the Food and Drug Administration is finally starting to take off after years of struggling financially — and it's about to get some long-promised funding from the FDA.
But some critics worry that this foundation, which will also raise money from private sources including industry, could provide a way for the food and medical industries to sway FDA decisions.